Journal
PHARMACEUTICAL STATISTICS
Volume 3, Issue 1, Pages 13-23Publisher
WILEY
DOI: 10.1002/pst.88
Keywords
bioequivalence; bootstrap; Cornish-Fisher approximation; method of moments; restricted maximum likelihood
Categories
Ask authors/readers for more resources
Since the early 1990s, average bioequivalence (ABE) has served as the international standard for demonstrating that two formulations of drug product will provide the same therapeutic benefit and safety profile. Population (PBE) and individual (IBE) bioequivalence have been the subject of intense international debate since methods for their assessment were proposed in the late 1980s. Guidance has been proposed by the Food and Drug A diministration (FDA) for the implementation of these techniques in the pioneer and generic pharmaceutical industries. Hitherto no consensus among regulators, academia and industry has been established on the use of the IBE and PBE metrics. The need for more stringent bioequivalence criteria has not been demonstrated, and it is known that the PBE and IBE criteria proposed by the FDA are actually less stringent under certain conditions. The statistical properties of method of moments and restricted maximum likelihood modelling in replicate designs will be summarized, and the application of these techniques in the assessment of ABE, IBE and PBE will be considered based on a database of 51 replicate design studies and using simulation. Copyright (C) 2004 John Wiley Sons Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available